OTCMKTS:CNBX CNBX Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.54 -0.21 (-5.60%) (As of 06/30/2022 11:21 AM ET) Add Compare Share Today's Range$3.54▼$3.5450-Day Range$3.50▼$10.4052-Week Range$3.00▼$23.18Volume947 shsAverage Volume959 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNBX Stock Forecast (MarketRank)Overall MarketRank™0.80 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for CNBX Pharmaceuticals. Previous Next 4.0 Community Rank Outperform VotesCNBX Pharmaceuticals has received 94 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCNBX Pharmaceuticals has received 62 “underperform” votes. (Add your “underperform” vote.)Community SentimentCNBX Pharmaceuticals has received 60.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CNBX Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCNBX Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNBX Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CNBX Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About CNBX Pharmaceuticals (OTCMKTS:CNBX)CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.Read More CNBX Stock News HeadlinesJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBXD)May 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 14, 2022 | barrons.comCNBX Pharmaceuticals Inc.May 5, 2022 | seekingalpha.comCNBX pharma granted patent in Hong Kong for cancer therapyMay 5, 2022 | finance.yahoo.comCNBX Pharmaceuticals Granted Patent in Hong KongApril 4, 2022 | msn.comNovartis to save at least $1 billion by 2024 thanks to simplified structureApril 4, 2022 | msn.comVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killerApril 4, 2022 | cnbc.comWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stakeApril 4, 2022 | msn.comStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreApril 1, 2022 | cnbc.comCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit TodayApril 1, 2022 | cnbc.comWhat to watch today: Wall Street set to wrap up strong month but weak quarterSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryCannabis SectorMedical Current SymbolOTCMKTS:CNBX CUSIPN/A CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A CNBX Pharmaceuticals Frequently Asked Questions How has CNBX Pharmaceuticals' stock price performed in 2022? CNBX Pharmaceuticals' stock was trading at $10.68 at the start of the year. Since then, CNBX stock has decreased by 66.9% and is now trading at $3.54. View the best growth stocks for 2022 here. When did CNBX Pharmaceuticals' stock split? How did CNBX Pharmaceuticals' stock split work? Shares of CNBX Pharmaceuticals reverse split on the morning of Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of CNBX Pharmaceuticals stock prior to the reverse split would have 1 shares after the split. Who are CNBX Pharmaceuticals' key executives? CNBX Pharmaceuticals' management team includes the following people: Mr. Gabriel Yariv, Pres, COO & Exec. Chairman (Age 45, Pay $241.79k)Mr. Eyal Barad, Co-Founder, CEO & Director (Age 57, Pay $268.72k)Dr. Eyal Ballan Ph.D., Co-Founder & CTO (Age 49, Pay $225.63k)Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52, Pay $76.4k)Noam Permont, VP of PR & Investor RelationsDr. Sigalit Ariely-Portnoy Ph.D., Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board (Age 58)Dr. Tal Mofkadi Ph.D., Financial Advisor & Member of Advisory BoardMr. Yasha Borstein, Chief Data Officer (Age 59)Dr. Yaakov Waksman, Head of Cannabidiol Research (Age 70)Dr. Ilya Reznik M.D., Head of Neuropsychiatry Devel. Who are some of CNBX Pharmaceuticals' key competitors? Some companies that are related to CNBX Pharmaceuticals include MassRoots (MSRT), Innovative Industrial Properties (IIPR), Cronos Group (MJN), Canopy Growth (WEED), CanniMed Therapeutics (CMED), OrganiGram (OGI), 22nd Century Group (XXII), Emblem (EMC), ICC Labs (ICC), GrowGeneration (GRWG), Leaf Mobile (LEAF), Bioventix (BVXP), Maple Leaf Green World (MGW), KushCo (KSHB) and Net Savings Link (NSAV). View all of CNBX's competitors. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), OrganiGram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA). What is CNBX Pharmaceuticals' stock symbol? CNBX Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX." How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CNBX Pharmaceuticals' stock price today? One share of CNBX stock can currently be purchased for approximately $3.54. How many employees does CNBX Pharmaceuticals have? CNBX Pharmaceuticals employs 10 workers across the globe. How can I contact CNBX Pharmaceuticals? CNBX Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The official website for CNBX Pharmaceuticals is www.cannabics.com. The company can be reached via phone at (877) 424-2429. This page (OTCMKTS:CNBX) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
